226 related articles for article (PubMed ID: 20933385)
21. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
[TBL] [Abstract][Full Text] [Related]
26. Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy.
Yang D; Liu X; Jiang X; Liu Y; Ying W; Wang H; Bai H; Taylor WD; Wang Y; Clamme JP; Co E; Chivukula P; Tsang KY; Jin Y; Yu L
J Control Release; 2012 Jul; 161(1):124-31. PubMed ID: 22521595
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
30. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
31. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
32. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
33. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
35. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice.
Zhang AL; Russell PJ
Cancer Lett; 2006 Feb; 233(1):185-91. PubMed ID: 15927363
[TBL] [Abstract][Full Text] [Related]
37. Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy.
Elsadek BEM; Hassan MH
Biochem Biophys Rep; 2021 Jul; 26():100966. PubMed ID: 33718631
[TBL] [Abstract][Full Text] [Related]
38. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer.
Rosato A; Banzato A; De Luca G; Renier D; Bettella F; Pagano C; Esposito G; Zanovello P; Bassi P
Urol Oncol; 2006; 24(3):207-15. PubMed ID: 16678050
[TBL] [Abstract][Full Text] [Related]
39. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
40. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Chen CT; Gan Y; Au JL; Wientjes MG
Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]